Trials / Completed
CompletedNCT02222467
Safety Evaluation of the KLOX BioPhotonic System in Venous Leg Ulcers
A Prospective Case Series Evaluating the Safety of the KLOX BioPhotonic System in Venous Leg Ulcers
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- KLOX Technologies Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of these case series is to evaluate the safety and tolerability of the KLOX BioPhotonic System as adjunctive therapy to Standard Of Care (SOC) in patients with venous leg ulcers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | KLOX BioPhotonic System | KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for venous leg ulcers. |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2015-04-01
- Completion
- 2015-11-01
- First posted
- 2014-08-21
- Last updated
- 2016-02-23
Locations
4 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT02222467. Inclusion in this directory is not an endorsement.